These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27824159)

  • 1. Oncometabolite D-2-Hydroxyglurate Directly Induces Epithelial-Mesenchymal Transition and is Associated with Distant Metastasis in Colorectal Cancer.
    Colvin H; Nishida N; Konno M; Haraguchi N; Takahashi H; Nishimura J; Hata T; Kawamoto K; Asai A; Tsunekuni K; Koseki J; Mizushima T; Satoh T; Doki Y; Mori M; Ishii H
    Sci Rep; 2016 Nov; 6():36289. PubMed ID: 27824159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia Induces Production of L-2-Hydroxyglutarate.
    Intlekofer AM; Dematteo RG; Venneti S; Finley LW; Lu C; Judkins AR; Rustenburg AS; Grinaway PB; Chodera JD; Cross JR; Thompson CB
    Cell Metab; 2015 Aug; 22(2):304-11. PubMed ID: 26212717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
    Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
    Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An hTERT/ZEB1 complex directly regulates E-cadherin to promote epithelial-to-mesenchymal transition (EMT) in colorectal cancer.
    Qin Y; Tang B; Hu CJ; Xiao YF; Xie R; Yong X; Wu YY; Dong H; Yang SM
    Oncotarget; 2016 Jan; 7(1):351-61. PubMed ID: 26540342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-13/STAT6 signaling plays a critical role in the epithelial-mesenchymal transition of colorectal cancer cells.
    Cao H; Zhang J; Liu H; Wan L; Zhang H; Huang Q; Xu E; Lai M
    Oncotarget; 2016 Sep; 7(38):61183-61198. PubMed ID: 27533463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of the oncometabolite enantiomers of 2-hydroxyglutarate and their metabolism by diverse dehydrogenases.
    Garcia I; Cornely K; Peterson CN; Berkmen MB
    Essays Biochem; 2024 Oct; 68(2):161-171. PubMed ID: 38919140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIF-1α Promotes Epithelial-Mesenchymal Transition and Metastasis through Direct Regulation of ZEB1 in Colorectal Cancer.
    Zhang W; Shi X; Peng Y; Wu M; Zhang P; Xie R; Wu Y; Yan Q; Liu S; Wang J
    PLoS One; 2015; 10(6):e0129603. PubMed ID: 26057751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).
    Grassian AR; Lin F; Barrett R; Liu Y; Jiang W; Korpal M; Astley H; Gitterman D; Henley T; Howes R; Levell J; Korn JM; Pagliarini R
    J Biol Chem; 2012 Dec; 287(50):42180-94. PubMed ID: 23038259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.
    Yuan BF
    Adv Exp Med Biol; 2021; 1280():161-172. PubMed ID: 33791981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
    Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
    Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncometabolite d-2HG alters T cell metabolism to impair CD8
    Notarangelo G; Spinelli JB; Perez EM; Baker GJ; Kurmi K; Elia I; Stopka SA; Baquer G; Lin JR; Golby AJ; Joshi S; Baron HF; Drijvers JM; Georgiev P; Ringel AE; Zaganjor E; McBrayer SK; Sorger PK; Sharpe AH; Wucherpfennig KW; Santagata S; Agar NYR; Suvà ML; Haigis MC
    Science; 2022 Sep; 377(6614):1519-1529. PubMed ID: 36173860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.
    Kalinina J; Ahn J; Devi NS; Wang L; Li Y; Olson JJ; Glantz M; Smith T; Kim EL; Giese A; Jensen RL; Chen CC; Carter BS; Mao H; He M; Van Meir EG
    Clin Cancer Res; 2016 Dec; 22(24):6256-6265. PubMed ID: 27340277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discordant intracellular and plasma D-2-hydroxyglutarate levels in a patient with IDH2 mutated angioimmunoblastic T-cell lymphoma.
    Churchill H; Naina H; Boriack R; Rakheja D; Chen W
    Int J Clin Exp Pathol; 2015; 8(9):11753-9. PubMed ID: 26617922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm.
    Rakheja D; Fuda F; Vandergriff T; Boriack R; Medeiros BC; Frankel AE; Chen W
    Hum Pathol; 2015 Feb; 46(2):322-6. PubMed ID: 25481493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEF2D Transduces Microenvironment Stimuli to ZEB1 to Promote Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer.
    Su L; Luo Y; Yang Z; Yang J; Yao C; Cheng F; Shan J; Chen J; Li F; Liu L; Liu C; Xu Y; Jiang L; Guo D; Prieto J; Ávila MA; Shen J; Qian C
    Cancer Res; 2016 Sep; 76(17):5054-67. PubMed ID: 27364559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH.
    Oizel K; Gratas C; Nadaradjane A; Oliver L; Vallette FM; Pecqueur C
    Cell Death Dis; 2015 Mar; 6(3):e1704. PubMed ID: 25811801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate.
    Fan J; Teng X; Liu L; Mattaini KR; Looper RE; Vander Heiden MG; Rabinowitz JD
    ACS Chem Biol; 2015 Feb; 10(2):510-6. PubMed ID: 25406093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZEB1 is neither sufficient nor required for epithelial-mesenchymal transition in LS174T colorectal cancer cells.
    Jägle S; Dertmann A; Schrempp M; Hecht A
    Biochem Biophys Res Commun; 2017 Jan; 482(4):1226-1232. PubMed ID: 27923654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.
    Shim EH; Livi CB; Rakheja D; Tan J; Benson D; Parekh V; Kho EY; Ghosh AP; Kirkman R; Velu S; Dutta S; Chenna B; Rea SL; Mishur RJ; Li Q; Johnson-Pais TL; Guo L; Bae S; Wei S; Block K; Sudarshan S
    Cancer Discov; 2014 Nov; 4(11):1290-8. PubMed ID: 25182153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.